AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
More positive results reported for Alzhemed.
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- At its annual general and special meeting of shareholders, Neurochem, Inc., (NRMX) announced additional positive interim results on cognitive function as measured by the ADAS-cog test in mild-to-moderate Alzheimer Disease (AD) patients participating in its ongoing open-label phase II extension study.
Neurochem is reporting on patients who have completed 9 and also 12 months of treatment on the highest dose (300 mg daily) of the investigational product candidate Alzhemed.
"To date, the majority of our patients treated with Alzhemed have stabilized or improved. Even though the numbers are not statistically significant, the results are impressive and have never been seen before," stated Dr. Francesco Bellini, chairman and CEO of Neurochem.
"The results obtained are consistent with all our previously reported data. Neurochem has a strong commitment to develop much awaited solutions to treat AD. The Alzhemed program is one part of our multipronged approach against this disease. Continuing research efforts and discovery are on-going and include much more potent second and third generation compounds as well as a synthetic vaccine program to prevent and treat AD," he added.
Most recent results in 23 mild-to-moderate patients using the ADAS-cog test indicate that patients treated with Alzhemed have shown an average score of +2.0 points after 9 months, as opposed to +5.0 points on average in comparable historical controls in a longitudinal study with AD patients. Of that group, 14 mild AD patients showed a score after 9 months of treatment of -0.8 ...
- Using historical controls to adjust for covariates in trend tests for binary...
- Magazine article from: Journal of the American Statistical Association Ibrahim, Joseph G. Ryan, Louise M. Chen, Ming-Hui December 1, 1998 700+ words
...likely due to this very limitation. Recently, Ibrahim and Ryan (1996) developed a method for incorporating historical controls into a time-adjusted test for carcinogenicity. Their approach extends Tarone's approach (which is based...
- Lung cancer in patients with human immunodeficiency virus infection compared...
- Newspaper article from: Cancer Weekly Sridhar, K.S. Flores, M.R. Raub, W. Richman, S.P. June 1, 1992 700+ words
AUTHORS: K.S. Sridhar, M.R. Flores, W. Raub and S.P. Richman. Sylvester Comprehensive Cancer Center, University of Miami School of Medicine and the V.A. Medical Center, Miami, Florida. According to the authors' abstract of a poster presentation to the 28th annual meeting of the American Society of
- Neurochem announces continued positive results for Alzhemed in open-label Phase...
- News wire article from: Asia Africa Intelligence Wire December 9, 2003 700+ words
...points on average in comparable historical controls in a longitudinal study...points on average in comparable historical controls. In five mild-to...5.0 on average in comparable historical controls. After 12 months...
- Neurochem announces continued positive results for Alzhemed(TM) in open-label...
- Press release article from: PR Newswire December 9, 2003 700+ words
...points on average in comparable historical controls in a longitudinal study...points on average in comparable historical controls. In five mild-to...5.0 on average in comparable historical controls. After 12 months...
- Positive results reported from Alzhemed trial after 12 months of treatment.
- Newspaper article from: Clinical Trials Week February 16, 2004 700+ words
...of +5.6 points in comparable historical controls. Mild AD patients...points on average in comparable historical controls. For the 30 mild...points on average in comparable historical controls with AD patients...
- Additional results in on-going Phase II extension study - Neurochem reports...
- News wire article from: Asia Africa Intelligence Wire January 22, 2004 700+ words
...of +5.6 points in comparable historical controls. Mild AD patients...points on average in comparable historical controls. For the 30 mild...points on average in comparable historical controls with AD patients...
- Neurochem's on-going open-label Phase II extension study for Alzhemed(TM) shows...
- Press release article from: PR Newswire July 18, 2004 700+ words
...points on average in comparable historical controls(6) with AD. A subset...points on average in comparable historical controls. Last April, the...points on average in comparable historical controls with AD. A subset...
- Additional Results In On-going Phase II Extension Study - Neurochem reports...
- Press release article from: PR Newswire January 22, 2004 700+ words
...of +5.6 points in comparable historical controls(5). Mild AD patients...points on average in comparable historical controls. For the 30 mild...points on average in comparable historical controls with AD patients...
- Neurochem reports results for fourth quarter and fiscal year 2004.
- Press release article from: PR Newswire February 22, 2005 700+ words
...points on average in comparable historical controls(5) with AD patients...points on average in comparable historical controls. The moderate AD patients...points on average in comparable historical controls. Similar to previously...
- Neurochem's on-going open-label Phase II extension study for Alzhemed shows...
- News wire article from: Asia Africa Intelligence Wire July 18, 2004 700+ words
...as opposed to +11.9 points on average in comparable historical controls with AD. A subset of mild AD patients responded...with a score of +8.6 points on average in comparable historical controls. The average CDR-SB score in the mild...
Source: HighBeam Research, More positive results reported for Alzhemed.